Table 3. Outcomes of Patients With Acute Ischemic Stroke Treated With Intravenous Thrombolysis by Selection Strategy.
| Outcome | Controls (n = 32 035) | All patients with recent ingestion of DOACs (n = 832) | DOAC plasma levels measured (n = 225) | Idarucizumab (n = 252) | Neither known levels nor idarucizumab (n = 355) |
|---|---|---|---|---|---|
| Primary outcome | |||||
| Symptomatic intracranial hemorrhage within 36 h, % (95% CI) | 4.1 (3.9-4.4) | 2.5 (1.6-3.8) | 3.1 (1.3-6.3) | 1.2 (0.2-3.4) | 3.1 (1.6-5.5) |
| Unadjusted OR (95% CI) | NA | 0.62 (0.40-0.96) | 0.66 (0.31-1.40) | 0.30 (0.09-0.92) | 0.84 (0.46-1.53) |
| P value | NA | .03 | .28 | .04 | .56 |
| Adjusted OR (95% CI) | NA | 0.57 (0.36-0.92) | 0.56 (0.26-1.21) | 0.36 (0.09-1.48) | 0.66 (0.35-1.25) |
| P value | NA | .02 | .14 | .16 | .20 |
| Secondary outcomes | |||||
| Any hemorrhagic transformation on follow-up imaging within 36 h, % (95% CI) | 17.4 (16.9-18.0) | 18.0 (15.4-20.9) | 20.5 (15.4-26.4) | 7.8 (4.5-12.4) | 22.2 (18.0-26.9) |
| Unadjusted OR (95% CI) | NA | 1.03 (0.85-1.24) | 1.23 (0.89-1.71) | 0.38 (0.23-0.63) | 1.40 (1.07-1.83) |
| P value | NA | .78 | .21 | <.001 | .02 |
| Adjusted OR (95% CI) | NA | 1.18 (0.95-1.45) | 1.13 (0.80-1.59) | 0.57 (0.32-1.01) | 1.58 (1.16-2.14) |
| P value | NA | .14 | .49 | .06 | .003 |
| Functional independence at 90 d, % (95% CI) | 57 (56-57) | 45 (41-49) | 40 (33-47) | 54 (46-62) | 44 (38-50) |
| Unadjusted OR (95% CI) | NA | 0.62 (0.53-0.73) | 0.50 (0.37-0.67) | 0.91 (0.66-1.25) | 0.60 (0.48-0.74) |
| P value | NA | <.001 | <.001 | .55 | <.001 |
| Adjusted OR (95% CI) | NA | 1.13 (0.94-1.36) | 0.85 (0.61-1.19) | 1.27 (0.84-1.91) | 1.29 (0.99-1.68) |
| P value | NA | .20 | .34 | .26 | .06 |
Abbreviations: DOAC, direct oral anticoagulant; NA, not applicable; OR, odds ratio.